I would have immediately had my ovaries removed. It would have been a no-brainer.
Eight miles from the English border, a postcode determined whether a woman would receive a genetic test that might have saved her from cancer — a quiet administrative boundary that carried the weight of a life-altering diagnosis. Heather Morgan's story, unfolding in Monmouthshire between 2014 and 2021, is a parable about how policy gaps between neighbouring nations can translate into profoundly unequal fates. Across the United Kingdom, the postcode lottery in hereditary cancer screening continues to distribute risk unevenly, reminding us that geography, not biology, too often governs who receives the gift of prevention.
- A Welsh woman diagnosed with breast cancer in 2014 was denied genetic testing available to English patients just eight miles away — a bureaucratic boundary that would later cost her the chance to prevent ovarian cancer.
- Seven years after that missed test, a lump in her abdomen confirmed what earlier screening might have forestalled: an ovarian cancer diagnosis carrying only a 35% chance of surviving the next decade.
- The disparity does not stop at the England-Wales border — even within England, Heather's two daughters living in different regions have received inconsistent invitations for the same genetic testing.
- A second Welsh woman carrying the BRCA2 mutation faces a different but equally charged dilemma: she must choose between continuing to breastfeed her child and maintaining the cancer screening protocol designed to protect her life.
- Wales has appointed a minister for preventative health and pledged a new cancer plan, but advocates warn that structural inequalities in hereditary screening remain deeply embedded across all UK nations.
Heather Morgan was 46 when she finished breast cancer treatment and received a letter explaining why she didn't qualify for genetic testing in Wales. Eight miles from the English border, her postcode had made her ineligible — even though women in England with the same diagnosis were being offered the test as standard in 2014. Wales was still building capacity, the letter said. By the time the policy aligned in 2015, Heather had moved on from treatment and was never recalled.
Seven years later, a lump in her abdomen led to a diagnosis of ovarian cancer. She is now 59, living with a 35% chance of surviving the next ten years. Had the genetic test taken place when it should have, she would have learned she carried a significantly elevated risk for ovarian cancer — and she says she would have had her ovaries removed without hesitation. The gap between two countries' policies, separated by eight miles, became the gap between prevention and diagnosis.
Her case is far from unique. Her two adult daughters, living in different parts of England, have had different experiences: one has been invited for genetic testing, the other has not. Wendy Watson, founder of the National Hereditary Breast Cancer Helpline, describes the pattern plainly — postcode lottery healthcare exists not just between England and Wales, but between health boards and trusts within each nation.
Elsewhere in Wales, Louise Owen, 36, carries the BRCA2 gene mutation and has undergone annual MRI screening since she turned 30. When she became pregnant and then began breastfeeding, she was told screening would have to pause due to reduced imaging accuracy. Her own research found no evidence supporting this restriction, but Breast Test Wales maintained the policy. As a breastfeeding peer support worker, Louise found herself forced to choose between her own cancer surveillance and nursing her child — a choice she describes with quiet fury.
The Welsh government has promised a new cancer plan with a focus on early detection and has appointed a minister for preventative health. For Heather, these steps arrive too late. She now volunteers with the National Hereditary Breast Cancer Helpline, helping others navigate the system that failed her — a system the helpline is working to expand, offering support for the very gene mutations that, identified a decade ago, might have spared her the life she is now fighting to keep.
Heather Morgan was 46 years old when she finished treatment for breast cancer. She kept the letter that arrived in the mail afterward—the one from Wales's genetic testing service explaining why she didn't qualify for the test that might have changed everything. Eight miles west of the English border, in Monmouthshire, her postcode had made her ineligible.
In England in 2014, women under 50 diagnosed with triple negative breast cancer were immediately offered genetic testing. In Wales, they were not. The Welsh government of the time was committed to meeting national guidance, the letter explained, but capacity for testing was still being built. By the time the rules aligned in 2015, Heather had already moved on from her treatment and was never invited.
Seven years later, in 2021, a visible lump in her abdomen led to further tests. She was diagnosed with ovarian cancer. Now 59, she carries a statistic that shapes how she thinks about the future: a 35 percent chance of surviving the next ten years. "I am mad annoyed," she said. "It's changed everything."
Had the genetic test happened in 2014, she would have learned that her genes put her at substantially higher risk for ovarian cancer. The response would have been straightforward. "I would have immediately had my ovaries removed," she said. "It would have been a no-brainer." Instead, the delay meant that cancer developed in the organ she might have chosen to remove before it became a threat. The difference between two countries' policies, separated by eight miles, became the difference between prevention and diagnosis.
Heather's case is not isolated. Her two adult daughters live in different parts of England—one in the north-east, one in the north-west. The younger daughter has been invited for genetic testing. The older has not. Wendy Watson, founder of the National Hereditary Breast Cancer Helpline, describes what she sees across the country: "We do have postcode lottery healthcare." The disparities exist not just between England and Wales but between health boards and trusts within each nation.
Louise Owen, 36, carries the BRCA2 gene mutation—a genetic marker that increases her lifetime risk of breast and ovarian cancers. She has known this for over a decade. When she turned 30, she began annual MRI screening, part of the protocol for people with inherited cancer risk. But when she became pregnant and then breastfeeding, she was told the screening would have to stop. The accuracy of the imaging would be reduced, she was told, due to changes in breast tissue.
Her own research suggested otherwise. Multiple medical sources concluded that MRI screening was safe during breastfeeding, with no evidence of risk to the baby. Yet Breast Test Wales maintained that the reduced accuracy of imaging during breastfeeding could lead to missed cancers or false positives requiring unnecessary biopsies. Louise, a breastfeeding peer support worker, faced a choice she felt she shouldn't have to make: continue screening or continue nursing her child. She had already stopped breastfeeding her first child sooner than she wanted, and the impact on her mental health had been significant. "I'm really angry about it," she said, "because I feel like why should I have to choose whether I get screening or whether I stop breastfeeding?"
The Welsh government has appointed a minister for preventative and public health to address these kinds of gaps and has promised an emphasis on early detection in a new cancer plan for Wales. But for Heather, the appointment comes too late. She now volunteers with the National Hereditary Breast Cancer Helpline, which recently opened its first information centre in the country, in Flint, north Wales. She helps others navigate the same system that failed to test her when it mattered. The helpline is expanding to offer support for cancers associated with BRCA gene mutations—the very mutations that, had they been identified in 2014, might have spared her the diagnosis she now lives with.
Notable Quotes
I would have immediately had my ovaries removed. It would have been a no-brainer.— Heather Morgan
We do have postcode lottery healthcare.— Wendy Watson, founder of the National Hereditary Breast Cancer Helpline
The Hearth Conversation Another angle on the story
When Heather got that letter in 2014 saying she wasn't eligible for the test, did anyone explain to her what she was missing—what the test could actually tell her?
The letter said Wales was working on capacity. But no one sat down and said, "If you had this test, here's what we'd know about your future risk." She only understood that later, after the ovarian cancer diagnosis.
So the policy changed in 2015. Why wasn't she retested then?
By 2015 she'd finished her breast cancer treatment. The system didn't go back and invite people who'd been excluded before. It was a one-time window that had already closed for her.
Her daughters—one invited for testing, one not—they live in the same country. How does that happen?
Different health trusts have different protocols. There's no single national standard, even within England. It's genuinely postcode lottery. Your postcode determines not just where you live but what screening you're offered.
Louise's situation with the breastfeeding and MRI screening seems like it should be solvable. The research says it's safe.
It should be. But Breast Test Wales is concerned about image quality during breastfeeding—reduced accuracy means potentially missing cancers or false alarms. Louise sees it as an unnecessary barrier. They see it as a clinical safeguard. Both are operating from real concerns, but the woman in the middle has to choose.
What does Heather do now with all this anger?
She volunteers with the helpline. She helps other people navigate the same gaps that caught her. It's not prevention, but it's something.